BPC-157: what the research actually shows
A 15-amino-acid pentadecapeptide with preclinical evidence for tissue repair. What buyers should know before comparing prices.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein fragment found in human gastric juice. The bulk of its scientific literature is preclinical — rodent models of tendon healing, ligament repair, and gastrointestinal inflammation dominate the research base. Human trials are limited.
What the preclinical literature suggests
Multiple animal studies (Sikiric et al., 2016+) report accelerated wound closure, reduced inflammation markers, and improved functional recovery after musculoskeletal injury. The peptide's proposed mechanisms include upregulation of VEGF and FAK, and modulation of NO/NOS signaling.
What human data exists
Direct human clinical trial data remains extremely limited as of 2026. Most reports are case series or open-label observational accounts. BPC-157 is not FDA-approved for any indication and is sold strictly as a research chemical.
Regulatory status
Research-use-only in the US, Canada, and UK. TGA Schedule 4 in Australia — personal import is tightly controlled. See the per-country panel on the product page for current status.
- Is BPC-157 legal to buy?
- For research use, yes, in most jurisdictions. For human consumption, no — it is not FDA-approved. See the per-country legality panel on the comparison page.
- Why do prices vary so much between vendors?
- Batch testing rigor, purity assays, cold-chain logistics, and vendor margin all contribute. The Pepticker rubric scores each vendor across 7 categories so the variance is auditable, not arbitrary.
- Sikiric et al., 2016 — BPC-157 tendon healing in rat. https://pubmed.ncbi.nlm.nih.gov/27165787/
- Chang et al., 2014 — BPC-157 in medial collateral ligament. https://pubmed.ncbi.nlm.nih.gov/24382146/